再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09688 再鼎医药

已收盘 11-12 16:08:06

21.020

+0.560

+2.74%

最高21.240	最低20.360	成交量482.64万
今开20.580	昨收20.460	日振幅4.30%
总市值262.96亿	流通市值262.96亿	总股本12.51亿
成交额1.01亿	换手率0.39%	流通股本12.51亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09688","market":"HK","secType":"STK","nameCN":"再鼎医药","latestPrice":21.02,"timestamp":1794470886008,"preClose":20.46,"halted":0,"volume":4826400,"delay":0,"changeRate":0.027370478983382147,"floatShares":1251000000,"shares":1251000000,"eps":-0.160262,"marketStatus":"已收盘","change":0.56,"latestTime":"11-12 16:08:06","open":20.58,"high":21.24,"low":20.36,"amount":101226358,"amplitude":0.043011,"askPrice":21.02,"askSize":23100,"bidPrice":21,"bidSize":2100,"shortable":3,"etf":0,"ttmEps":-1.244,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794533400000},"marketStatusCode":5,"adr":0,"listingDate":1601222400000,"exchange":"SEHK","adjPreClose":20.46,"openAndCloseTimeList":[[1794447000000,1794456000000],[1794459600000,1794470400000]],"volumeRatio":0.736518,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09688","defaultTab":"news","newsList":[{"id":"1117464336","title":"再鼎医药11月12日发行约710万股股份，占已发行股本约0.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=1117464336","media":"公告速递","labels":["SGX"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117464336?lang=zh_cn&edition=full","pubTime":"2026-11-12 18:01","pubTimestamp":1794477710,"startTime":"0","endTime":"0","summary":"再鼎医药有限公司（09688）于2026年11月12日公告，基于先前已披露的股权激励计划，分别向参与人及董事发行新股，合计约710万股股份。其中，向参与人发行约630.11万股，占当时已发行股本约0.5%；另向董事发行约79.89万股，占当时已发行股本约0.06%。发行股份每股价格为0港元。\n本次股份发行完成后，公司已发行股本由2026年10月31日的12.51亿股增至12.58亿股。公司在公告中表示，相关发行已获董事会正式授权，并严格遵守香港联合交易所有限公司证券上市规则及相关法律法规。公告由公司秘书F. Ty Edmondson签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"再鼎医药11月12日发行约710万股股份，占已发行股本约0.56%","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682569295","title":"再鼎医药(09688.HK)根据股份计划发行合计710万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2682569295","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682569295?lang=zh_cn&edition=full","pubTime":"2026-11-12 17:59","pubTimestamp":1794477587,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1574","LU2488822045.USD","09688","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682456929","title":"再鼎医药(09688)根据股份计划发行合计710万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2682456929","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682456929?lang=zh_cn&edition=full","pubTime":"2026-11-12 17:59","pubTimestamp":1794477587,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，于2026年11月12日，就根据股份计划授予参与人(发行人的董事除外)的股份奖励或期权而发行合计710万股新股或转让库存股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1522366.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1588","LU2488822045.USD","BK4526","BK4548","BK4588","ZLAB","BK4139","09688","BK1161","BK1574","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682561708","title":"再鼎医药：11月12日发行新股710万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2682561708","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682561708?lang=zh_cn&edition=full","pubTime":"2026-11-12 17:59","pubTimestamp":1794477540,"startTime":"0","endTime":"0","summary":"21财经11月12日电，再鼎医药（09688.HK）发布翌日披露报表，2026年11月12日，公司根据股权激励计划向参与人及董事发行新股合计710万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611123929729449.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611123929729449.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ZLAB","BK1574","BK4548","BK1588","09688","BK1161","BK4531","BK4139","LU2488822045.USD","BK4585","BK4526","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682532911","title":"创新药板块局部走强 华昊中天医药-B（02563）涨近6% 机构看好出海BD与产业链配套机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2682532911","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682532911?lang=zh_cn&edition=full","pubTime":"2026-11-12 10:45","pubTimestamp":1794451530,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药板块局部走强，截至发稿，华昊中天医药-B 涨5.91%，同源康医药-B涨5.68%，再鼎医药涨2.05%，欧康维视生物-B涨1.82%，锦欣生殖涨1.75%，百济神州涨1.19%。除药品本身的销售前景外，他还看好复杂结构新药上市后带来的合同研发生产服务需求，以及临床研究、安全性评价和核心原辅料等环节的机会。此外，中信建投证券认为，短期内，业绩改善有望带动相关企业估值修复。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995876","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02563","BK1583","LU1770034418.SGD","LU1719994722.HKD","09688","02410","01951","LU0828237510.HKD","LU1251922891.USD","LU1303224171.USD","LU0228659784.USD","BK1191","06160","BK1597","BK1219","BK1515","BK1500","09939","159992","KURE","159938","LU2488822045.USD","BK1588","01477","MEDX","IBBQ","LU1969619763.USD","06978","BK1161","LU0307460666.USD","LU0588546209.SGD","LU2328871848.SGD","LNGR","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682888725","title":"纳斯达克中国金龙指数跌超1%，JDZG跌6.67%，网易跌4.12%，小鹏汽车跌2.76%，再鼎医药跌2.65%，BOS","url":"https://stock-news.laohu8.com/highlight/detail?id=2682888725","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682888725?lang=zh_cn&edition=full","pubTime":"2026-11-11 22:31","pubTimestamp":1794407511,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2929501877.USD","BK4532","ZLAB","BK4548","IE00BYV24P56.USD","LU1880383440.USD","LU1152091754.HKD","LU1688375341.USD","BK4531","BK4099","BK4503","LU0072913022.USD","LU0994945656.USD","LU0067412154.USD","BK4505","09868","LU1043141123.HKD","ODDS","IE00BVYPNQ40.USD","IE00BGHQDM52.EUR","LU1880383366.USD","IE00BMCWC346.EUR","LU1960683339.HKD","IE00BVYPNP33.GBP","LU1807302812.USD","09688","BK4509","BK4563","BK4077","BK4577","BZ","09999","BK4585","BK4085","ESPO","LU0426417589.USD","BK4139","LU2187417386.USD","HERO","LU1023057109.AUD","LU1152091168.USD","LU2488822045.USD","LU2351347302.SGD","BK4539","BK4130","LU1993786604.SGD","XPEG","LU0359202008.SGD","LU1008478684.HKD","LU1121112475.USD","BK4535","BK4551","IE00B29SXG58.USD","LU1228905540.USD","LU0880133367.SGD","BK4588","LU0545562505.USD","02076","NERD","NTES","BK4514","BK4526","XPEV","LU0426412945.USD","BK4204","BK4501","LU0501845795.SGD","LU1043141396.HKD","HK0000165453.HKD","LU2039709279.SGD","LU0359201612.USD","BK4555","LU1228905037.USD","EVS.SI","JDZG","HXC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682315662","title":"再鼎医药(09688.HK)授出部分购股权、受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2682315662","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682315662?lang=zh_cn&edition=full","pubTime":"2026-11-10 22:07","pubTimestamp":1794319659,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1588","BK1574","LU2488822045.USD","BK1161","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198763755","title":"再鼎医药（09688）授出5,900份ADS期权及16,900个ADS限制性股票单位","url":"https://stock-news.laohu8.com/highlight/detail?id=1198763755","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198763755?lang=zh_cn&edition=full","pubTime":"2026-11-10 22:01","pubTimestamp":1794319296,"startTime":"0","endTime":"0","summary":"11月10日，再鼎医药有限公司发布公告称，公司已于2026年11月9日根据《2024年股权激励计划》向合资格雇员授出部分购股权及限制性股票单位，以奖励员工并进一步激励团队。表现目标及退扣机制：无附带表现目标，亦无退扣机制；受公司在2024年股权激励计划项下的税务扣缴条款规限。根据公告，在本次授出后，“2024年股权激励计划”下尚余61,687,193股普通股可供未来授出。公告由再鼎医药董事会主席兼首席执行官杜莹于2026年11月10日发布。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116480573","title":"再鼎医药10月股份变动月报：新增发行113,400,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1116480573","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116480573?lang=zh_cn&edition=full","pubTime":"2026-11-09 18:06","pubTimestamp":1794218760,"startTime":"0","endTime":"0","summary":"再鼎医药于2026年11月9日发布10月股份变动月报表，报告期为2026年10月。公告显示，公司截至本月底的注册股本维持5,000,000,000股不变，对应法定注册股本30,000美元。公司本月新增发行113,400,000股普通股，发行价格为每股17.28港元，发行完成后已发行股份规模由9月底的1,137,828,030股增至1,251,228,030股。截至10月底，公司确认符合香港联交所规定的公众持股量和相关法规要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682820601","title":"生物医药板块走强 再鼎医药（09688）涨超13% 全球医药融资回暖支撑创新药与CXO景气上行","url":"https://stock-news.laohu8.com/highlight/detail?id=2682820601","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682820601?lang=zh_cn&edition=full","pubTime":"2026-11-09 10:08","pubTimestamp":1794190084,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药板块走强，截至发稿，再鼎医药 涨13.07%，康诺亚-B涨7.22%，康方生物涨6.33%，科伦博泰生物涨5.36%，药明生物涨4.96%，金斯瑞生物科技涨4.48%，复宏汉霖涨4.04%。2026年上半年，全球生物科技融资、License交易、并购交易金额分别达到502亿美元、1667亿美元和960亿美元，均显著超越去年上半年，医药融资及License交易持续回暖，为医药研发提供了资金支持。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995489","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002562.SGD","BK1588","LU0359201612.USD","LU1242518931.SGD","LU0051755006.USD","MEDX","09688","LU0320764243.SGD","BK4581","LU1242518857.USD","159938","HK0000165453.HKD","LU0181495838.USD","LU0348784397.USD","06990","LU0029874061.USD","IBBQ","LU1794554557.SGD","02162","159992","LU2039709279.SGD","ZLAB","09939","LU2476274308.USD","06978","01548","02696","LNGR","CXO","LU0348767384.USD","399441","LU0348825331.USD","BK1610","LU0543330566.HKD","09926","KURE","BK4588","LU0561508036.HKD","XBI","161726","LU0516423091.SGD","LU0196878994.USD","BK1574","LU0456827905.SGD","WX","LU0140636845.USD","02269","LU0456846285.SGD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682277218","title":"再鼎医药早盘涨逾12% 第三季度产品收入1.076亿美元环比增长2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2682277218","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682277218?lang=zh_cn&edition=full","pubTime":"2026-11-09 09:50","pubTimestamp":1794189000,"startTime":"0","endTime":"0","summary":"模拟交易客户端再鼎医药早盘涨逾12%。截至发稿，股价上涨11.77%，现报20.52港元，成交额5130.878万港元。再鼎医药近日披露2026年第三季度业绩。报告期内，公司总收入为1.082亿美元，其中产品收入净额为1.076亿美元，环比增长2%，主要得益于纽再乐的市场覆盖率和渗透率提升，以及呫诺美林曲司氯铵的上市。2027年将是关键之年，公司有望在美国递交zoci的首个生物制品上市许可申请。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-11-09/doc-iniyazcy6374236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4526","BK4585","ZLAB","BK4548","BK1588","09688","BK1574","LU2488822045.USD","BK1161","BK4531","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154592423","title":"港股直击｜医药股、AI 应用股、半导体股、黄金股齐上扬，再鼎医药、优必选升10%，灵宝黄金升6%， 华虹宏力升4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1154592423","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154592423?lang=zh_cn&edition=full","pubTime":"2026-11-09 09:41","pubTimestamp":1794188470,"startTime":"0","endTime":"0","summary":"医药股、AI 应用股、半导体股、黄金股齐上扬， $再鼎医药(09688)$、 $优必选(09880)$升 10%， $歌礼制药-B(01672)$升 9%，灵宝黄金升 6%， 华虹宏力升 4%。","market":"hk","thumbnail":"https://static.tigerbbs.com/2a3253accc7322a3db322a8557ee9834","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/2a3253accc7322a3db322a8557ee9834"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01860","09880","09688","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682382730","title":"港股异动 | 再鼎医药(09688.HK)再涨超10% 三季度产品收入1.076亿美元 Zoci全球临床研发取得新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2682382730","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682382730?lang=zh_cn&edition=full","pubTime":"2026-11-09 09:35","pubTimestamp":1794188124,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09688","BK1161","BK1588","LU2488822045.USD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681686076","title":"纳斯达克中国金龙指数涨超1%，禾赛科技涨9.50%，晶科能源涨8.65%，阿特斯涨7.90%，小牛电动涨7.47%，再鼎","url":"https://stock-news.laohu8.com/highlight/detail?id=2681686076","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681686076?lang=zh_cn&edition=full","pubTime":"2026-11-06 23:09","pubTimestamp":1793977766,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CSIQ","LU2488822045.USD","BK4585","HSAI","LU2778985437.USD","BK4555","BK4531","BK4548","BK4588","BK4091","BK4141","BK4526","02525","LU2476274308.USD","BK4139","09688","BK4519","NIU","ZLAB","BK4558","HXC","BK4124","LU2476274720.SGD","JKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681867114","title":"纳斯达克中国金龙指数涨超0.5%，禾赛科技涨8.33%，再鼎医药涨7.30%，蔚来涨4.38%，晶科能源涨3.21%，小","url":"https://stock-news.laohu8.com/highlight/detail?id=2681867114","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681867114?lang=zh_cn&edition=full","pubTime":"2026-11-06 22:37","pubTimestamp":1793975869,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4509","BK4526","BK4505","BK4534","BK4551","09868","09688","09866","02525","BK4585","BK4519","LU0320764599.SGD","NIOG","BK4139","LU2476274308.USD","BK4504","BK4531","BK4099","BK4141","HSAI","NIO.SI","LU0052750758.USD","EVS.SI","BK4588","LU0708995583.HKD","BK4124","LU2476274720.SGD","BK4581","HXC","XPEV","BK4555","LU2778985437.USD","JKS","BK4574","BK4532","BK4548","NIO","ZLAB","LU2488822045.USD","XPEG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681107880","title":"再鼎医药（09688）盘中涨近2% 三季度产品收入净额环比增长2% 预计明年多个全球项目成为催化剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2681107880","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681107880?lang=zh_cn&edition=full","pubTime":"2026-11-06 10:13","pubTimestamp":1793931223,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再鼎医药 盘中震荡走高，截至发稿，最新报18.51港元，涨幅1.87%，成交额3121.83万港元。消息面上，公司公告披露，2026年第三季度总收入为1.082亿美元，去年同期为1.161亿美元。公司产品收入净额为1.076亿美元，环比增长2%。期内亏损净额为4,610万美元。研发开支为4,980万美元，SG&A开支为7,010万美元，同比均基本持平。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995400","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","ZLAB","BK4548","BK4585","BK1588","BK1161","BK4139","BK4526","09688","BK4531","LU2488822045.USD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681884019","title":"【券商聚焦】中信建投评26 ESMO：中国创新药持续突破，竞争与差异化并存","url":"https://stock-news.laohu8.com/highlight/detail?id=2681884019","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681884019?lang=zh_cn&edition=full","pubTime":"2026-11-06 08:57","pubTimestamp":1793926628,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年欧洲内科肿瘤学会（European Society for Medical Oncology，ESMO）中，中国创新药在多瘤种领域全面发力，众多项目从早期探索迈入III期临床或BLA/NDA阶段。国内药企已在IO双抗及多抗、ADC、小分子靶向等赛道形成多线并进格局，III期阳性终点多点开花，持续产出具备国际竞争力的临床数据，标志着中国创新药研发不断从跟随创新迈向源头创新与全球引领的新阶段，行业发展逻辑从“fast-follow”迈入“first-in-class”与“best-in-class”并行的阶段。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995351","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","LU0516422952.EUR","LU0348766576.USD","LU0456827905.SGD","LU0540923850.HKD","LU1242518857.USD","LU0128522744.USD","01177","01801","LU1242518931.SGD","IE00BPRC5H50.USD","LU0039217434.USD","02142","LU0348783233.USD","LU1152091754.HKD","LU0228659784.USD","02616","01093","LU1226287529.USD","LU2097828474.EUR","LU1251922891.USD","LU0708995153.HKD","BK1583","09926","LU0594300179.USD","01877","06185","BK1515","06160","LU0823426308.USD","09995","LU1960683339.HKD","02269","09688","LU0320764243.SGD","LU1152091168.USD","LU0417516571.SGD","LU2488822045.USD","LU0315179316.USD","LU1188198961.HKD","BK1191","LU0634319403.HKD","601066","LU2097828714.EUR","KURE","LU1813983027.USD","KCE","LU0455707207.USD","LU2242644610.SGD","LU1807302812.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109476003","title":"再鼎医药更新10月股份变动月报表，获增发113,400,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1109476003","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109476003?lang=zh_cn&edition=full","pubTime":"2026-11-05 21:01","pubTimestamp":1793883701,"startTime":"0","endTime":"0","summary":"再鼎医药于2026年11月5日披露了截至2026年10月31日的股份变动月报表，披露了公司在10月期间的股本结构及相关变动情况。本次月报显示，公司法定注册股本为5,000,000,000股普通股，每股面值0.000006美元，总额为30,000美元，与上月保持一致。月初已发行股份为1,137,828,030股。公司表示，截至目前无库藏股持有或注销情况。截至2026年10月31日，公司普通股股份总数为1,251,228,030股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183270594","title":"再鼎医药（09688）公布2026年三季报：收入1.08亿美元同比下降7%，净亏损扩大至4614万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1183270594","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183270594?lang=zh_cn&edition=full","pubTime":"2026-11-05 20:20","pubTimestamp":1793881242,"startTime":"0","endTime":"0","summary":"再鼎医药有限公司今日在香港交易所公告，并向美国证券交易委员会提交截至2026年9月30日止第三季度Form 10-Q。2026年第三季度公司实现总收入1.08208亿美元，较2025年同期的1.16095亿美元下降7%。期内产品收入净额为1.07648亿美元，同比下降7%；合作收入为0.56百万美元，同比下降24%。净亏损4613.6万美元，较上年同期的3596.3万美元增加28%；普通股基本及摊薄每股亏损0.04美元。累计净亏损1.47977亿美元，同比扩大18%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681027516","title":"再鼎医药(09688)第三季度总收入达1.082亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681027516","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681027516?lang=zh_cn&edition=full","pubTime":"2026-11-05 20:12","pubTimestamp":1793880765,"startTime":"0","endTime":"0","summary":"再鼎医药(09688)发布公告，2026年第三季度总收入为1.082亿美元，2025年同期为1.161亿美元。2026年第三季度产品收入净额为1.076亿美元，2025年同期为1.154亿美元。产品收入净额环比增长2%，主要得益于纽再乐(受益于市场覆盖率和渗透率的提升)和呫诺美林曲司氯铵(于2026年6月上市)，部分被肿瘤电场治疗因胶质母细胞瘤市场竞争格局变化导致收入下滑所抵销。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/gonggaonew/ganggugongg20.jpg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggaonew/ganggugongg20.jpg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1519252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","BK4526","BK4588","BK4139","BK4531","LU2488822045.USD","BK1588","BK4548","BK4585","09688","BK1161","ZLAB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":0.136},{"period":"1month","weight":0.0596},{"period":"3month","weight":-0.0068},{"period":"6month","weight":0.2716},{"period":"1year","weight":0.1979},{"period":"ytd","weight":0.4989}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":0.0018},{"period":"3month","weight":-0.0425},{"period":"6month","weight":-0.0634},{"period":"1year","weight":-0.0892},{"period":"ytd","weight":-0.0513}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"再鼎医药有限公司是一家主要从事生物制药业务的控股公司。该公司致力于通过产品的发现、开发和商业化解决肿瘤、免疫、神经科学和感染性疾病领域未被满足的医疗需求。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物，其中包括“则乐”、“OPTUNE”、“擎乐”、“纽再乐”及“卫伟迦”等。该公司在国内市场和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.017355},{"month":2,"riseRate":0.666667,"avgChangeRate":0.068855},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.098942},{"month":4,"riseRate":0.666667,"avgChangeRate":0.061043},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.046017},{"month":6,"riseRate":0.5,"avgChangeRate":-0.004904},{"month":7,"riseRate":0.666667,"avgChangeRate":0.052949},{"month":8,"riseRate":0.666667,"avgChangeRate":0.046005},{"month":9,"riseRate":0.5,"avgChangeRate":-0.038078},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.066637},{"month":11,"riseRate":0.571429,"avgChangeRate":0.065914},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.024481}],"exchange":"SEHK","name":"再鼎医药","nameEN":"ZAI LAB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,09688,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}